Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 dose-ranging prophylaxis study in hereditary angioedema
2016-001272-29Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of berotralstat in hereditary angioedema (HAE) (6 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Number of confirmed HAE attacks. Started Apr 2016; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2016-001272-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001272-29.